Shortly after the market closed on June 30, Biogen Inc. and Exelixis Inc. confirmed leadership changes that will result in Exelixis's long-time CEO George Scangos, PhD, taking the helm of the Big Biotech July 15. The move is counterintuitive, both for the commercial-stage Biogen and for Scangos, whose career has largely been focused on research and early development and free of activist shareholder pressure.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?